Clinical Trial Update: Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Amikacin Liposome Inhalation Suspension for Mycobacterium xenopi pulmonary disease. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Xenopi Pulmonary Disease

Drugs mentioned

• Amikacin Liposome Inhalation Suspension (amikacin liposome inhalation suspension)

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Mycobacterium; Xenopi, Lung Diseases | Phase 2 | Status: RECRUITING